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Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive deterioration of
cognitive functions, extracellular b-amyloid (Ab) plaques and intracellular neurofibrillary tangles within neocortex and
hippocampus. Adult hippocampal neurogenesis plays an important role in learning and memory processes and its
abnormal regulation might account for cognitive impairments associated with AD.
Methodology/Principal Findings: The double transgenic (Tg) CRND8 mice (overexpressing the Swedish and Indiana
mutations in the human amyloid precursor protein), aged 2 and 6 months, were used to examine in vivo the effects of 5
weeks lithium treatment. BrdU labelling showed a decreased neurogenesis in the subgranular zone of Tg mice compared to
non-Tg mice. The decrease of hippocampal neurogenesis was accompanied by behavioural deficits and worsened with age
and pathology severity. The differentiation into neurons and maturation of the proliferating cells were also markedly
impaired in the Tg mice. Lithium treatment to 2-month-old Tg mice significantly stimulated the proliferation and neuron
fate specification of newborn cells and fully counteracted the transgene-induced impairments of cognitive functions. The
drug, by the inhibition of GSK-3b and subsequent activation of Wnt/ß-catenin signalling promoted hippocampal
neurogenesis. Finally, the data show that the lithium’s ability to stimulate neurogenesis and cognitive functions was lost in
the aged Tg mice, thus indicating that the lithium-induced facilitation of neurogenesis and cognitive functions declines as
brain Ab deposition and pathology increases.
Conclusions: Lithium, when given on time, stimulates neurogenesis and counteracts AD-like pathology.
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Introduction
In the adult Central Nervous System (CNS), neurogenesis
occurs throughout the lifetime. Adult neurogenesis is a process by
which new neurons are produced from neural stem cells (NSCs)
and has consistently been found in two ‘‘neurogenic regions’’ of
the brain in vivo: the subgranular zone (SGZ) of dentate gyrus
(DG) in the hippocampus, which supplies new neurons for the
dentate granular cell layer (GCL) and the subventricular zone
(SVZ) lining the lateral ventricles in the forebrain, which supplies
new interneurons for the olfactory bulb [1],[2]. Adult NSCs have
the ability to self-renew and to differentiate into neurons,
astrocytes and oligodendrocytes in all mammalian CNS, includ-
ing humans [3]. In both SGZ and SVZ neurogenic regions,
neurogenesis progress as a multi-step process which starts with the
proliferation of NSCs. For the hippocampus, conceptually, this
process has been divided into four steps: (i) proliferation of NSCs,
(ii) neuronal fate determination of NSCs, (iii) survival and
maturation of new neurons and (iv) functional integration of new
neurons into the pre-existent neuronal network [4]. Functionally,
hippocampal neurogenesis appears to play an important role in
learning and memory processes and mood regulation and its
abnormal regulation might account for cognitive impairments
associated with Alzheimer’s disease (AD) and may underlie
neuropsychiatric disorders like major depression [5–7]. Irregular-
ities in adult neurogenesis in patients and AbPP overexpressing
models of AD have been previously observed and reported. Some,
although not all, in vivo studies using AD animal models indicate
that decreased neurogenesis may be due to the increased
deposition of amyloid-b (Ab) and the subsequent formation of
Ab plaques [8] and in vitro studies suggest that proliferation of
neuronal stem/progenitor cells is inhibited by Ab peptide [9].
Stem cells differentiation is controlled by both intrinsic and
extrinsic regulators. Among the extracellular factors that regulate
this process are found the Wnt ligands. Of note, it has been
shown that Wnt-3 is expressed near the SGZ in adult mice, that
the Wnt canonical pathway plays an active role in the adult
hippocampus [10] where it regulates adult neurogenesis pro-
moting proliferation and differentiation of NSC (see ref. in
[11]and in [12]). Glycogen synthase kinase-3b(GSK-3b) inhib-
itors stimulate neuronal differentiation and the mood stabilizer
lithium, through activation of the canonical Wnt pathway,
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14382
enhances proliferation of adult hippocampal progenitors in vitro
inducing them to become neurons at therapeutically relevant
concentrations [13].
In this study we sought to determine the effects of 5 weeks
lithium treatment to TgCRND8 mice, of 2 and 6 months of age,
representing the early and advanced stages of Ab deposition
respectively, on hippocampal neurogenesis and how it correlates
with a reduced brain pathology and behavioural impairments.
Here we demonstrate that lithium, via inhibition of GSK-3 and
subsequent activation of Wnt/b-catenin signalling, stimulates
adult hippocampal progenitor cells proliferation and neuronal
differentiation, ameliorates cognitive functions and reduces Ab
deposition in 3-month-old TgCRND8 mice. The ability of lithium
treatment to stimulate hippocampal neurogenesis and to amelio-
rate cognitive impairments is lost in advanced stage of the disease
in the TgCRND8 mice.
Results
Cell proliferation in the SGZ of 3-month-old wild type
and TgCRND8 mice and effect of lithium salts
In the attempt to examine whether or not the Ab deposition
triggers progenitor cell proliferation, saline-injected control and
Tg mice were administered BrdU during the last 3 days of
treatment and were then sacrificed 24 h after the final BrdU
injection. Mice of both genotypes displayed newly generated cells
mostly in the SGZ of DG of the hippocampus, as shown by the
fluorescent BrdU immunoreactivity (IR) (Fig. 1 A,C), which labels
the nuclei of replicating cells irrespective of cell lineage. Notably,
quantitative analysis of BrdU+ cells revealed a significant 31%
reduction in the number of proliferating cells in the saline-treated
Tg compared to saline-treated wt mice (Fig. 1 I), thus indicating
that the neurodegenerative process associated with the transgene
expression dramatically dampens the proliferation. Following
lithium treatment the proliferation of neural progenitor cells in
the SGZ of DG appeared to be increased in both wt and Tg mice
(Fig. 1 B,D). Quantitative analysis of the fluorescent BrdU+ cells
demonstrated a significantly higher number of proliferating cells in
the lithium-treated Tg than in saline-treated Tg mice (Fig. 1 I). In
order to determine whether these newly generated cells commit to
neuronal differentiation, a double staining with DCX and BrdU
antibodies was performed. At 24 h after BrdU administration the
vast majority of BrdU+ cells in the SGZ was found within DCX+
cells in all groups (Fig. 1 E–H). Next, we counted and quantified
the number of BrdU+/DCX+ stained cells and statistical analysis
revealed a significant reduction in the percentage of newborn
neurons in the saline-treated Tg compared to saline-treated wt
mice (Fig. 1 J). In the Tg mice lithium treatment significantly
increased the neuronal proliferation of BrdU+ cells up to control
values (Fig. 1 J). Double labelling immuno-histochemistry with
BrdU and GFAP antibodies revealed no or very few BrdU+/
GFAP+ stained cells in the SGZ of both wt and Tg mice,
regardless of treatment.
Newborn cell survival and migration into the dentate
gyrus
To judge the relevance of the neurogenesis process, the survival
and differentiation of SGZ progenitors were examined 5 weeks
after the last BrdU administration to an additional group of 2-
month-old wt and Tg mice. Both saline-treated wt and Tg mice
showed fewer BrdU+ cells compared to the respective wt and Tg
mice at 24 h after BrdU injection (30% and 26% of survival in the
wt and Tg mice, respectively), indicating that many of SGZ
progenitors do not survive to maturity. Significantly fewer BrdU+
cells were detected (Fig. 2 C) and counted (Fig. 2 E, *P,0.05) in
the SGZ of saline-treated Tg relative to saline-treated wt
mice(Fig. 2 A). Importantly, lithium treatment completely
recovered the survival rate of progenitors in the Tg mice (Fig. 2
D and E, #P,0.01). To investigate the phenotype of these
survived cells, triple immunohistochemical analysis of BrdU with
NeuN and GFAP was carried out. BrdU+ cells almost entirely
differentiated into neurons (Fig. 2, J vs E), being the majority
detected in the SGZ-GCL and a few in the hilus (Fig. 2 F–I).
Consistent with the immunohistochemical analysis, more than
90% of the newborn BrdU+ cells migrated into the SGZ-GCL
neuronal network and the remaining into the hilus, with no
differences between groups (Fig. 2 K). Quantitative analysis of the
NeuN-immunoreactive BrdU+ cells within the SGZ-GCL (Fig. 2 J)
demonstrated that more than 95% of the newborn cells were
mature neurons and that new neuron survival was significantly
(*P,0.05) lower in the saline-treated Tg mice compared to saline
controls. Lithium treatment significantly (#P,0.01) restored the
new neuron survival in the Tg mice. According to previous studies
a variety of morphological characteristics such as size, shape and
staining pattern reflect maturity of new cells [14–16]. Therefore
we checked for the morphological aspect of the BrdU/NeuN co-
stained cells. In the SGZ-GCL of saline-treated Tg mice an equal
amount of BrdU+ cells with solid and punctate staining patterns
was detected (Fig. 2 L,M), indicating that roughly a 50% of
newborn cells reached maturity. Notably, in the lithium-treated
Tg mice the percentage of BrdU+ cells with punctate aspect raised
up to 70–80%, not differing from the wt groups. Taken together
these data indicate that lithium treatment counteracts the
abnormal maturation of newborn neurons which is undergoing
in the Tg mice.
Cell proliferation in the SGZ of aged wild type and
TgCRND8 mice and effect of lithium salts
In 7-month-old saline-treated TgCRND8 mice, characterized
by an extensive cerebral Ab deposition, plaque- associated gliosis
and tau hyperphosphorylation [17], and in age-matched wt mice a
few BrdU+ cells were detected in the SGZ (Fig. 3 A,C). In these
mice the number of BrdU+ cells in the SGZ was significantly
reduced compared to the respective 3-month-old mouse group (Tg
mice: 39.561.96 in 7-month-old vs 84.2768.38 in 3-month-old,
253%, P,0.01; wt mice: 77.0663.49 in 7-month-old vs
122.5966.76 in 3-month-old, 237%, P,0.01), indicating a
decreased cell proliferation with age, irrespective of genotype.
Moreover, in the 7-month-old saline-treated mice, quantitative
analysis (Fig. 3 I) revealed a significant reduction in the number of
BrdU+ cells in Tg compared to wt mice (249%, *P,0.001).
Altogether these findings indicate that cell proliferation is
markedly reduced both by aging and the increasing severity of
pathology in the transgenic mice. A 5-week lithium treatment to 7-
month-old mice significantly increased the proliferation of BrdU+
cells in the wt mice, but not in the Tg mice, compared to saline
treatment (#P,0.001). We next checked for the presence of
BrdU/DCX co-labelled cells and found that the majority of
newborn cells expressed DCX and were therefore committed to a
neuronal phenotype, irrespective of both treatment and genotypes
(Fig.3 E–H). Quantification of the percentage of BrdU+/DCX+
cells (Fig. 3 J) revealed a significant reduction in the saline-treated
Tg mice compared to saline-treated wt mice (**P,0.05) and no
enhancement in the percentage of newborn neurons was brought
about by lithium treatment in both genotypes. As above reported
for the group of 3 months, no or only a few BrdU+ cells
differentiated into astrocytes, regardless of treatment.
Lithium on AD-Like Pathology
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Figure 1. Cell proliferation in the SGZ of 3-month-old wt and TgCRND8 mice and effect of lithium treatment. A–D: BrdU+ (green) cells
of neurogenic dentate gyrus area of saline-treated wt (A) and Tg (C) and of lithium-treated wt (B) and Tg (D) mice. E–H: double labelling
immunohistochemical analysis for BrdU and DCX staining showing that the vast majority of BrdU+ cells (green) co-localized with DCX (red). White
arrows indicate some co-localizing cells. Scale bars: 100mm (A–D), 50 mm (E–H). Insets in E–H: higher magnifications of the cells indicated by the
arrows. I and J, quantitative analysis of the number of BrdU+ cells and of the new immature neurons (BrdU+/DCX+), respectively, in the SGZ of wt and
Tg groups. The number of the BrdU+cells and the percentage of the BrdU+/DCX+ cells were significantly reduced in the saline-treated Tg compared to
saline-treated wt mice: *P,0.05. Lithium significantly increased the number of these proliferating cells: *P,0.05, lithium-treated Tg vs saline-treated
Tg mice. One-way ANOVA plus Bonferroni’s post-comparison test. wt: wild type; Tg: TgCRND8, S: saline, L: lithium.
doi:10.1371/journal.pone.0014382.g001
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Effects of lithium salts on Ab burden in the TgCRND8
mouse brain
As next step we investigated whether the improved neurogenesis
triggered by lithium treatment might result from a reduced
amyloid load/plaques formation (Fig. 4 A–D). In the cortex and
hippocampus of saline-treated 3-month-old Tg mice amyloid
plaques were few and round shaped, ranging in size from small to
medium, with a maximum plaque area of about 180 mm2. In these
brain areas substantial differences in the amyloid load were
brought about by 5 weeks of lithium treatment. Quantitative
analysis of amyloid burden (Fig. 4 E,F) showed a significant
lithium treatment effect in the total Ab plaque area, in the plaque
number and in the minimum and maximum plaque areas, both in
the neocortex and hippocampus. Altogether, these findings
demonstrate a robust lithium effect in the 3-month-old Tg mice
with an early Ab deposition. APP phosphorylated on threonine
688 (Thr688) by aberrant activation of GSK-3 has been reported
to increase Ab generation [18]. To investigate whether a reduction
of phospho-APP(Thr668) was underlying the reduced Ab burden
the levels of phospho-APP(Thr668) were analyzed in 3-month-old
TgCRND8 mice. By Western blotting, phospho-APP(Thr688)
levels were significantly reduced in the cortex and hippocampus
of lithium-treated Tg compared with saline-treated Tg mice
(Fig. 4 G,H).
In the cortex and hippocampus of 7-month-old saline-treated
mice, amyloid plaques were numerous, ranging from small and
round shaped, sometimes forming clusters, to big and radiating
with a dense core and a maximum plaque area of about 700 mm2
(Fig. 5 A,C). A 5-week lithium treatment significantly reduced the
plaque number and the minimum plaque area (Fig. 5 B,D). A
more in depth morphological analysis revealed that in the lithium-
treated group some radiating plaques displayed a less dense core
with fewer and smaller round-shaped deposits in its surroundings
compared to controls, as exemplified in the higher magnifications
for the hippocampus (Fig. 5 E, F). Consistent with this, Thioflavin
S histochemistry showed in the brain of lithium-treated 7-month-
old Tg mice several radiating b-sheeted plaques with ribbon-like/
diffuse cores and less compact deposits in their surroundings (Fig. 5
H). Taken together, these findings suggest that the lithium’s ability
to reduce the formation of Ab deposits is maintained at the late
stage of the pathology.
Lithium salts reduced glia reaction in the brain of 3-
month-old TgCRND8 mice
Fluorescent immunohistochemical analysis revealed diminished
parenchyma and plaque-associated inflammation in lithium-
treated 3-month-old Tg mice, involving both IBA-1-labelled
microglial cells and GFAP-immunoreactive astrocytes. IBA-1
antibody showed microglial cells with small cell bodies and thin
and elongated processes, both in the neocortex and hippocampus,
in the lithium-treated Tg (Fig. 6 B,D), compared to saline-treated
Tg mice (Fig. 6 A,C), where microglial cells with enlarged cell
bodies and short and thickened processes were found. By GFAP
immunostaining hypertrophic astrocytes with long and thick
branches were detected in the neocortex and in all the subregions
of the hippocampus of saline-treated Tg mice (Fig. 6 E,G,I). By
contrast, in the same brain areas of lithium-treated Tg mice (Fig. 6
F,H,J) astrocytes reaction occurred at much less extent. Accord-
ingly, quantitative analysis of GFAP blots revealed a significant
reduction of GFAP protein levels in the lithium-treated Tg mice
compared to Tg controls (Fig. 6 K,L).
Lithium salts inhibited GSK-3b in the TgCRND8 mouse
brain
In neuronal cells lithium can inhibit GSK-3b either directly or
indirectly by activating Akt, thus leading to increased Ser9
phosphorylation and consequent inactivation of the kinase. Wexler
et al. [13] reported that the inhibition of GSK-3b by lithium
results in the activation of the canonical Wnt signalling pathway
which positively regulates adult neural progenitors. In order to
examine whether lithium’s ability to enhance neuronal differen-
tiation was mediated by GSK-3b inhibition coronal brain sections
from 3-month-old Tg mice were immuno-labelled with p-GSK-
3b(Ser9) antibody, which is specific for the inactive isoform of the
kinase. An increased immunoreactivity was found in the deep
layers of the parietal neocortex and in the subfields of the
hippocampus, as shown for the SGZ of DG and CA3 area, of the
lithium-treated 3-month-old TgCRND8 mice as compared to the
corresponding brain areas of saline-treated age-matched Tg mice
(Fig. 7 A–D). Western blotting analysis detected higher p-GSK-
3b(Ser9) protein levels in the entire hemicortex and hippocampus
of lithium-treated Tg compared to saline-treated Tg mice (Fig. 7
E). Of note, no differences were found in the cortical and
hippocampal levels of total GSK-3b among the four groups (Fig. 7
F). Accordingly, the expression of the active isoform of GSK-3b
was significantly reduced, both in immunohistochemical and
Western blotting analyses, in the cortex and hippocampus of
lithium-treated 3-month-old TgCRND8 mice compared to saline-
treated age-matched Tg controls (Fig. 7 G–K). In parallel,
Western blotting experiments aimed at investigating Akt activation
following lithium treatment were carried out employing p-
Akt(Ser473) antibody, which is specifically raised against the
activated isoform of the kinase. Quantification of protein band
intensities demonstrated significant increases in p-Akt(Ser473)
levels in the cortex and hippocampus of lithium-treated 3-month-
old Tg mice as compared to the age-matched Tg controls (Fig. 7
L), indicating that an Akt-mediated inactivation of GSK-3b is also
undergoing in lithium-treated animals.
The inhibition of GSK-3b by lithium was achieved also in the
group of 7-month-old TgCRND8 mice as demonstrated by the
Figure 2. Cell survival in the SGZ-GCL of 3-month-old wt and TgCRND8 mice and effect of lithium treatment. A–D:
immunohistochemical detection of BrdU+ cells (green) 5 weeks after the last administration of BrdU in the saline (A) and lithium (B)-treated wt
and in the saline (C) and lithium (D)-treated Tg mice. Scale bar = 200 mm (A–D). E: quantification of the BrdU+ cells, *P,0.05, Tg vs wt, saline-treated
group; #P,0.01 lithium-treated Tg vs saline-treated Tg mice. F–I: triple labelling immunohistochemistry with BrdU (green), NeuN (red) and GFAP
(blue) antibodies demonstrating the co-localization of BrdU and NeuN and their migration into the SGZ-GCL in the saline (F)- and lithium (G)-treated
wt and saline (H)- and lithium (I)-treated Tg mice. Arrow in H indicates a newborn cell in the hilus region. Scale bar = 50 mm (F–I); J: quantitative
analysis of the number of BrdU+ that was NeuN+ in the SGZ-GCL. A lower number of BrdU+/NeuN+ cells was found in the saline-treated Tg compared
to saline-treated wt mice (*P,0.05) and this number recovered to control values following lithium treatment (#P,0.01, lithium-treated Tg vs saline-
treated Tg mice). K: quantitative analysis of the number of newly-born neuron migrated into SGZ-GCL and hilus regions. L: quantitative analysis of the
number of newborn cells with a solid BrdU appearance and a representative photomicrograph showing a cell with a solid staining pattern. *P,0.05,
saline-treated Tg vs wt groups and vs lithium-treated Tg mice. M: quantitative analysis of the number of newborn cells with a punctate BrdU
appearance and a representative photomicrograph showing a cell with a punctate staining pattern. *P,0.05, saline-treated Tg vs wt groups and vs
lithium-treated Tg mice. One-way ANOVA plus Bonferroni’s post-comparison test. wt: wild type, Tg: TgCRND8, S = saline, L = lithium.
doi:10.1371/journal.pone.0014382.g002
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higher p-GSK-3b(Ser9) protein levels detected in the neocortex
and hippocampus of lithium-treated Tg compared to saline-
treated age-matched Tg mice (Fig. 8 A–C). In these aged mice we
have previously reported the occurrence of abnormal tau
hyperphosphorylation at different sites [17]. A large body of
evidence indicates that GSK-3 activation, together with other tau
kinases, plays a key role in tau phosphorylation, whereas its
inhibition is neuroprotective [19,20]. By Western Blotting we
demonstrated a statistically significant reduction in the levels of
PHF-1 immunopositive tau, both in the cortex and hippocampus
of lithium-treated TgCRND8 mice as compared to saline-treated
age-matched Tg mice (Fig. 8 D–F).
Figure 3. Cell proliferation in the SGZ of 7-month-old wt and TgCRND8 mice and effect of lithium salts. A–D: BrdU (green)
immunohistochemical analysis of neurogenic dentate gyrus area in the hippocampus of saline-treated wt (A) and Tg (C) and of lithium-treated wt (B)
and Tg (D) mice. Scale bar = 200 mm (A–D). E-H double labelling with BrdU (green) and DCX (red) in the SGZ of saline-treated wt (E) and Tg (G) and of
lithium-treated wt (F) and Tg (H) mice. White arrows indicate co-localizing cells. White arrowheads in H and G indicate a non neuronal newborn cell.
Scale bar = 50mm (E–H ). I: bar graph showing the number of BrdU+ cells within the neurogenic dentate gyrus area, *P,0.001 vs saline-treated wt
mice. J: bar graph showing the percentage of BrdU+ cells that was DCX+ in the SGZ. *P,0.05, vs saline-treated wt mice. One-way ANOVA plus
Bonferroni’s post hoc test. wt: wild type; Tg: TgCRND8, S = Saline, L = Lithium.
doi:10.1371/journal.pone.0014382.g003
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Lithium salts activated canonical Wnt pathway in 3-
month-old TgCRND8 mice
To determine the relative involvement of the canonical Wnt/b-
catenin pathway activation in the lithium-induced neuronal
proliferation and differentiation of hippocampal progenitors,
downstream to GSK-3b, we evaluated, firstly, whether, as a
consequence of GSK-3b inactivation, the intracellular expression
of b-catenin was enhanced and, secondly, whether the new
generated neurons expressed b-catenin. Single immunohistochem-
istry revealed increased b-catenin immunoreactivity throughout
the neocortex and the subfields of the hippocampus, as shown for
the GCL of DG, of lithium-treated Tg as compared to saline-
treated Tg mice (Fig. 9 A–D). Next, in triple labelling fluorescence
performed with DCX and b-catenin antibodies plus DAPI (Fig. 9
E–J), we observed that in the SGZ of lithium-treated Tg mice the
number of DCX positive neurons (red) expressing b-catenin
(green) at the nuclear level (Fig. 9 H–J) was higher than in the
saline-treated Tg mice (Fig. 9 E–G). This suggests that lithium, by
GSK-3b inhibition, facilitates b-catenin nuclear translocation and,
thereby, promotes adult hippocampal neurogenesis in vivo by
activating downstream Wnt/b-catenin target genes.
Lithium salts improved cognitive impairments in 3-
month-old but not in 7-month-old TgCRN8 mice
At the end of the fourth week of treatment the mice were
evaluated for cognitive functions in the ‘‘Step down’’ inhibitory
avoidance test. During the training test no significant differences
were observed between the four groups of animals of 3 and 7
months of age. In the 24 h retention test, the step-down latencies
recorded for the saline-treated TgCRND8 mice were significantly
reduced as compared to saline-treated wt mice. Lithium treatment
resulted in a significant memory improvement of 3-month-old Tg
mice (Fig. 10 A). These results indicate that lithium salts treatment
to 2-month-old Tg mice is capable to completely prevent cognitive
impairment. By contrast, lithium was unable to counteract the
transgene-related cognitive impairments in 7-month-old Tg mice
(Fig. 10 B).
During the fifth week of treatment 3-month-old Tg and wt mice
were trained for four days in the MWM task to learn where the
hidden platform was located. The animals were naive to the water
maze and showed no deficiencies in swimming abilities, directional
swimming toward the platform, or climbing onto an hidden
platform during training trials. Saline- and lithium-treated wt mice
significantly shortened the escape latency during the acquisition
phase over sessions (Fig. 11 A), they were good swimmers and
responded for being placed in water with an appropriate swim-
search response. Lithium-treated TgCRND8 mice showed
reduced escape latency as compared to saline-treated Tg mice
during the last three days of training. Two-way ANOVA revealed
a significant lithium treatment effect on escape latency in Tg mice
(F (1,9) = 7,61, P,0.0001, treatment factor) and Bonferroni’s post
hoc multiple comparison test revealed significantly shorter escape
latencies in the wt groups throughout the training period (P,0.001
saline- and lithium-treated wt vs saline-treated Tg) and in lithium-
treated Tg on day 2 (uP,0.01), 3 (NP,0.05) and 4 (*P,0.001) with
respect to saline-treated Tg mice, indicating that lithium markedly
ameliorated cognitive abilities in Tg mice.
The development of spatial memory for the platform location
during the training sessions was evaluated in a probe trial
administered 5 h after the last test on day 4. The analysis revealed
that lithium-treated Tg and saline- and lithium-treated wt mice
spent a significantly higher percentage of time in the target section
in which the platform was previously located than saline-treated Tg
mice (*P,0.05, lithium-treated Tg vs saline-treated Tg; NP,0.001
saline- and lithium-treated wt vs saline-treated Tg) (Fig. 11 C). The
swim speed in quadrants was comparable among the groups,
indicating that the mice were not impaired in motility and
exploratory behavior. As above reported for the ‘‘step down’’ test,
the performance of 7-month-old saline-treated Tg mice in the
MWMwas impaired as compared to age-matched saline-treated wt
mice and lithium treatment was unable to produce any significant
amelioration in all the MWM paradigms evaluated (Fig. 11 B,D).
Discussion
The purpose of the present study was to examine whether
chronic lithium treatment can potentially be effective in
ameliorating the cognitive deficits associated with AD by
stimulation of cell proliferation and survival and integration of
newborn cells into neuronal network of the SGZ-GCL of the
hippocampus in a mouse model of AbPP deposition. In addition,
we sought to determine whether the facilitation of neurogenesis by
lithium was through the activation of the Wnt/b-catenin signalling
pathway. To this purpose we used TgCRND8 mice, harbouring
two mutant human APP genes [21], at 3 and 7 months of age,
representing the early and advanced stages of Ab deposition. In
this transgenic mouse strain, in agreement with findings in other
mouse models of AD with distinct genetic mutations that underlie
their pathology [22,23] we have found a decreased neurogenesis in
the SGZ of the hippocampus. The decrease of hippocampal
neurogenesis was associated with behavioural deficits and
developed with age, in parallel with the development of AD-like
pathology presently and previously reported in this Tg mouse
strain [17,21,24,25]. The survival, differentiation into neurons and
maturation of the proliferating cells were also markedly impaired
in the transgenic mice. Lithium salts treatment to 2-month-old Tg
mice significantly stimulated the proliferation and neuron fate
specification of newborn cells and fully counteracted the
transgene-induced impairments of cognitive functions. Moreover,
our results showing lithium-induced GSK-3b inhibition and b-
catenin increase, indicate that lithium promotes hippocampal
neurogenesis through the activation of GSK-3b/b-catenin path-
way and thereby enhances the expression of proneural genes. On
the other side, our findings demonstrate that lithium’s ability to
stimulate neurogenesis and cognitive functions is impaired in the
aged Tg mice characterized by an extensive Ab plaques deposition
and suggest that the pathway(s)/mechanism(s) underlying the
lithium-induced facilitation of neurogenesis and cognitive func-
tions decline as brain Ab deposition and pathology increases.
Figure 4. Lithium reduced Ab burden and phospho-APP(Thr668) levels in 3-month-old TgCRND8 mouse brain. A–D representative
photomicrographs of Ab (1–42) immunolabelled amyloid plaques in the cortex (A,B) and hippocampus (C,D) of saline-treated (A,C) and lithium-
treated (B,D) Tg mice. E,F: Quantitative analyses of the total area, plaque number and minimum and maximum plaque area in the cortex and
hippocampus of saline-and lithium-treated Tg mice. Note in B and D and in the bar graphs the significant reduction of amyloid load by lithium
treatment (Student’s t-test, *P,0.05, #P= 0.02, **P,0.01 versus Tg saline). Scale bar = 100 mm applies to all images. (G) qualitative Western blotting
analysis of p-APP(Thr668) levels. b-actin was used as a protein loading control. (H) Quantitative analysis of protein levels showing a statistically
significant decrease of p-APP(Thr668) levels in the cortex and hippocampus of lithium-treated Tg mice compared with saline-treated Tg controls.
(One-way ANOVA plus Bonferroni’s post hoc test,*P,0.05 versus Tg saline).
doi:10.1371/journal.pone.0014382.g004
Lithium on AD-Like Pathology
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Figure 5. Lithium treatment reduced the de novo formation of Ab plaques in 7-month-old TgCRND8 mouse brain. A–D:
immunohistochemical detection of Ab plaques in the cortex (A,B) and hippocampus (C,D) of saline-treated (A,C) and lithium-treated (B,D) 7-month-
old TgCRND8 mice. Scale bar = 200 mm (A–D). E,F: higher magnifications of the squared areas in C and D, respectively. Note in F a radiating plaque in
the lithium-treated group displaying a less dense core with fewer and smaller round-shaped deposits in its surroundings compared to the radiating
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Several mouse models recapitulating features of AD pathology
have been used to investigate whether the process of neurogenesis
is altered in the disease and whether it contributes to cognitive
impairments (see refs in [26]). In vitro and in vivo studies reported a
suppressive toxic effect of Ab 1–42 on human and mouse neural
stem cells [9]. Accordingly, we found that the number of
proliferating cells in the SGZ undergoes a marked and progressive
age- and Ab load-related reduction. In the TgCRND8 mice the
first Ab deposits appear at the age of 3 months and, become
numerous and widespread throughout the hippocampus and
cortex at the older age of 7 months [21]. Not only the proliferation
of neural progenitor cells was decreased in the Tg mice, but also
their differentiation into mature neurons and functional integra-
tion into the pre-existing neuronal network were more strongly
reduced in the Tg mice compared to controls. Newborn neurons
leaving the SGZ have been shown to migrate mainly into the
adjacent GCL of the DG of adult rodents [27]. Accordingly, 5
weeks after the last BrdU administration we found that the
majority of BrdU+ cells migrated into the adjacent granular layer
and a very few cells into the hilus, irrespective of genotype.
Newborn cells, influenced by multiple factors, undergo complex
stages of morphological and functional maturation [28]. After a 5-
week survival period, the newborn cells in the SGZ-GCL
displayed either solid or punctate BrdU staining, punctate BrdU
positive neurons were significantly lower in the TgCRND8 mice
compared to controls, likely as a consequence of the hippocampal
Ab deposition as well as other age-related dysfunctions. The
reduction of newborn cells with a punctate BrdU staining in the
Tg mice likely reflect a retarded maturation in newborn SGZ-
GCL neurons, as previously reported [14,29].
plaque in E of the saline-treated group. Scale bar = 25 mm (E–F). G,H: Thioflavin S histochemistry of a radiating Ab plaque in the saline (G)-and lithium
(H)-treated Tg mice. Note in H the ribbon-like morphology of the b-amyloid plaque core and the reduction of compact deposits in the main amyloid
core surroundings compared to the Ab load in the G image. Scale bar = 25 mm (G–H). I,J: in bar graphs are reported the quantitative analyses of the
total area, plaque number and minimum and maximum plaque area in the cortex and hippocampus of saline-and lithium-treated Tg mice. Only the
plaque number and the minimum plaque area resulted significantly reduced by lithium treatment *P,0.05 versus Tg saline, Student’s t-test.
doi:10.1371/journal.pone.0014382.g005
Figure 6. Lithium reduced glia activation in the 3-month-old TgCRND8 mouse brain. A–D: representative photomicrographs of merged
fluorescent immunohistochemical analysis of IBA-1 (green) labelled microglial cells plus DAPI (blue) in the cortex (A,B) and CA1 area of the
hippocampus (C,D) of saline-treated (A,C) and lithium-treated (B,D) TgCRND8 mice. Insets a-d: higher magnifications of the IBA-1 positive cells
indicated by the arrows in each image. Note that microglial cells in the lithium treated mice have smaller cell bodies and thinner and elongated
processes (magnified b and d images) than in saline controls, where microglial cells display swollen cell bodies and short and thick processes
(magnified a and c images). Scale bar = 50 mm (A–D). Scale bar = 25 mm (a–d). E–J: representative photomicrographs of GFAP immunoreactivity in the
cortex, CA1 and dentate gyrus of the hippocampus of saline- (E,G,I) and lithium- (F,H,J) treated TgCRND8 mice showing a reduced astrocytes reaction
in the lithium group. Scale bar = 100 mm applies for all images. K,L: qualitative and quantitative analyses of GFAP Western blots in the cortex (K) and
hippocampus (L) of saline- and lithium-treated Tg mice. Cortex: *P,0.05, saline-treated Tg vs saline-treated wt and vs lithium-treated Tg mice;
hippocampus: **P,0.01 saline-treated Tg vs saline-treated wt mice, *P,0.05 saline-treated Tg vs lithium-treated Tg mice, one-way ANOVA plus
Bonferroni’s post hoc test. Ctx: cortex; DG: dentate gyrus.
doi:10.1371/journal.pone.0014382.g006
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The newly generated neurons in the hippocampal formation
and their incorporation into DG circuits support spatial memory
(for refs see [30]) and cognitive stimuli promote the survival of
newborn cells [31]. Thus, an interplay seems to exist in the
hippocampus between neurogenesis and learning and memory
functions which in the young TgCRND8 mice is positively
Figure 7. Effect of lithium treatment on the expression of GSK-3b isoforms and pAkt(Ser473) in the 3-month-old TgCRND8 mouse
brain. A–D: representative photomicrographs of p-GSK-3b(Ser9) immunoreactivity in the cortex and hippocampus of saline (A,C)- and lithium (B,D)-
treated TgCRND8mice showing an increased p-GSK-3b(Ser9) immunoreactivity in the deep layers of the parietal neocortex (B) and in the hippocampus
(D) of the lithium group compared to the saline group. Arrows in D indicate the p-GSK-3b(Ser9) immunoreactivity in the CA3 and dentate gyrus of the
hippocampus. Scale bar: 100 mm (A–D). E and F: qualitative Western blotting and densitometric analysis of p-GSK-3b(Ser9) and total GSK-3b bands,
respectively. b-actin serves as a protein loading control. Statistics indicate a significant increase of p-GSK-3b (Ser9) levels in the neocortex and
hippocampus of lithium-treated 3-month-old Tg mice compared with the age-matched controls and no differences in the total GSK-3b expression
among the groups. *P,0.05, vs saline-treated Tg. Two-way ANOVA plus Bonferroni’s post hoc test. G–J: representative photomicrographs of active
GSK-3b immunoreactivity in the cortex and dentate gyrus of the hippocampus of saline (G,I)- and lithium (H,J)-treated TgCRND8mice. Note fewer active
GSK-3b positive cells in the parietal neocortex (H) and hippocampus (J) of the lithium group compared to the saline group. Arrows in I and J indicate the
GSK-3b immunoreactivity in the dentate gyrus. Scale bar:100 mm (G–J). K: qualitative Western blotting and densitometric analysis of p-GSK-3b(Tyr216)
protein levels in the cortex and hippocampus of saline- and lithium-treated TgCRND8 mice. Statistics indicate a significant reduction of p-GSK-
3b(Tyr216) levels in the cortex and hippocampus of lithium-treated 3-month-old Tg mice compared with the age-matched controls. Student’s t test:
*P,0.05, lithium-treated Tg vs saline-treated Tg mice. (L) qualitative Western blotting and densitometric analysis of pAkt(Ser473) in the cortex and
hippocampus of saline- and lithium-treated wt and Tg mice. Statistics indicate a slight but significant increase in the levels of this kinase by lithium
treatment in the Tg mice. Two-way ANOVA plus Bonferroni’s post hoc test: *P,0.05, saline-treated Tg vs lithium-treated Tgmice. Data are presented as
mean 6 S.E.M. b-actin serves as a protein loading control. Ctx: Cortex; Hippo: hippocampus, S = saline, L = lithium, Tg: TgCRND8.
doi:10.1371/journal.pone.0014382.g007
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modulated by lithium. In fact, lithium administration for 5 weeks
to 2 month-old Tg mice significantly increased cell proliferation,
neuronal differentiation, survival and correct maturation of BrdU+
cells in the SGZ-GCL and significantly ameliorated the behav-
ioural performance in the MWM and ‘‘Step down’’ tests. At the
same time the entire Ab burden was significantly reduced, likely as
a prevention of Ab deposition, by 5 weeks of lithium treatment.
Hence, it is feasible that lithium, by reducing Ab burden, promotes
neurogenesis and restores cognitive functions in 3-month-old
TgCRND8 mice. Moreover, the Ab plaque-associated gliosis in
the Tg mice was attenuated as the Ab deposition was decreased by
lithium, supporting an apparent anti-inflammatory role of lithium.
The lithium’s ability to stimulate hippocampal neurogenesis and to
recover cognitive functions was lost in the 7-month-old
Figure 8. Effect of lithium treatment on the inactive p-GSK-3b(Ser9) and PHF-1 immunoreactivity in the 7-month-old TgCRND8
mouse brain. A: qualitative Western blotting and (B,C) densitometric analysis of p-GSK-3b(Ser9) in the cortex and hippocampus of 7-month-old
TgCRND8 mice. Statistics indicate a significant increase of p-GSK-3b(Ser9) levels in the neocortex and hippocampus of lithium-treated 7-month-old Tg
mice compared with the age-matched controls. *P,0.05, vs saline-treated Tg. Two-way ANOVA plus Bonferroni’s post hoc. D: qualitative Western
blotting and (E–F) densitometric analysis of PHF-1 protein levels in the cortex and hippocampus of saline- and lithium-treated Tg mice. Statistics
indicate a significant reduction of PHF-1 levels in the neocortex and hippocampus of lithium-treated 7-month-old Tg mice compared with the age-
matched Tg controls. Data are presented as mean 6 S.E.M. *P,0.05, saline-treated Tg vs lithium-treated Tg mice, Student’s t-test. b-actin serves as a
protein loading control. S = saline, L = lithium, Tg: TgCRND8.
doi:10.1371/journal.pone.0014382.g008
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TgCRND8 mice. The Ab burden in the old Tg mice was mostly
represented, throughout the brain parenchyma, by big and
radiating plaques with a dense Ab core which was not significantly
reduced by lithium treatment, as indicated by the lack of treatment
effect in the maximum Ab plaque area. However, the lithium-
treated 7-month-old group showed some radiating plaques with a
ribbon-like deposit rather than a dense Ab core and fewer small
and round-shaped amyloid deposits in the main core surround-
ings. Furthermore, in these mice the minimum Ab plaque area,
represented by the small and round-shaped plaques, which might
consist of amyloid plaques in formation, was significantly reduced
by lithium treatment, once again indicating that lithium treatment
prevents rather than removes/dissolves Ab deposits. Altogether
these data indicate, firstly, that lithium, while intervening only
partly on previously formed plaques, represented by those with the
maximum Ab plaque area, significantly counteracts the gradual
build up of Ab deposits and, secondly, that a stronger amyloid load
reduction is needed to stimulate neurogenesis and to recover
cognitive functions. In 3-month-old TgCRND8 mice, the lithium-
induced reduction in Ab load was associated with a significant
reduction in APP phosphorylation and in 7-month-old TgCRND8
mice with a decrease in PHF-1 tau hyperphosphorylation. It is
known that lithium at therapeutic concentrations inhibits GSK-3b
activity directly, by competition with the enzyme for a magnesium-
binding site, and indirectly, by phosphorylation of serine-9 in the
pseudosubstrate domain of the enzyme through the activation of
Akt [32]. Consistent with previous findings [33], here we
demonstrate that lithium treatment significantly reduced the
active GSK-3b while increased the levels of inactive GSK-3b by
activation of Akt. Although other mechanisms might also be
involved, our data suggest that lithium, via inhibition of GSK-3b,
triggers a cascade of protective events ranging from the activation
of the canonical Wnt pathway to a reduction of APP phosphor-
ylation and thereby a lesser accumulation of Ab, to a reduction of
Figure 9. Lithium activated Wnt/b -catenin pathway in the SGZ of 3-month-old TgCRND8 mouse brain. A–D: single b-catenin
immunohistochemistry in the saline (A,C)- and lithium (B,D)-treated Tg mouse brain. An apparently higher number of b-catenin positive cells is
present in the parietal cortex and dentate gyrus of the hippocampus of lithium-treated Tg mice compared to Tg controls. Scale bar = 50mm (A–B).
Scale bar = 100mm (C–D). E–J: triple labelling fluorescence for b-catenin (green), DCX (red) and DAPI (blue) staining. E–G: saline treated Tg mice, G
merge of E and F images plus DAPI. H–J lithium-treated Tg mice, J merge of H and I images plus DAPI. White arrows in G and J indicate the nuclear
co-localization of DCX and b-catenin staining in the saline-and lithium-treated Tg mice, respectively. Scale bar = 12.5 mm (E–J). sgz: sub granular zone,
ctx: cortex; DG: dentate gyrus, Tg: TgCRND8, S = saline, L = lithium.
doi:10.1371/journal.pone.0014382.g009
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tau hyperphosphorylation and of glia reaction in the brain of Tg
mice. Likewise, recent studies have shown that therapeutic
concentrations of lithium inhibit APP processing at or before the
c-secretase cleavage step and block the accumulation of Ab
peptides in brain of mice overproducing Ab [34]. Moreover,
compounds that inhibit GSK-3 could lead to the reduction of both
the formation of amyloid plaques and neurofibrillary tangles. Here
we demonstrate that lithium by the inhibition of GSK-3 increases
b-catenin expression throughout the neocortex and hippocampus
of TgCRND8 mice likely leading to the activation of Wnt/b-
catenin signalling. Strongly supportive of this, our data revealed
that in the lithium-treated Tg mice b-catenin is mainly expressed
at the nuclear level of the newborn neurons while in the saline-
treated Tg mice it remained mostly confined to the cytosol. Thus,
the regulation of Wnt target genes transcription by nuclear
translocation of b-catenin may underlie the increased cell
proliferation and neuronal differentiation stimulated by lithium
treatment. Noteworthy, Wnt signalling has been identified as an
endogenous pathway that regulates hippocampal neurogenesis, as
evidenced by the expression of receptors and signalling compo-
nents for Wnt proteins within adult hippocampal stem/progenitor
cells [10,35,36]. Furthermore, Wnt/b-catenin is active and
triggers the expression of NeuroD1 in the hippocampal neurogenic
niche of mice [35–37]. Inhibition of Wnt abolishes almost
completely hippocampal neurogenesis and differentiation in vivo
[38]. The enhanced neurogenesis/survival in the SGZ has been
proposed as the mechanism which causes the improvement in
memory test [39] and a prevention of behavioural disturbances by
lithium, through an activation of Wnt signalling, has been reported
in a mouse model of AD [33]. Consistent with this study we found
that a 5-week lithium treatment completely recovers the water
maze and step down performances of 3-month-old Tg mice with
an early amyloid pathology. Concomitantly with this, the
activation of Wnt/b-catenin signalling and the stimulation of
neurogenesis in the SGZ were observed. In 7-month-old
TgCRND8 mice, although a GSK-3b inhibition was undertaken
resulting in a significant reduction in hyperphosphorylated tau
protein, neither behavioural recovery nor neurogenesis activation
was brought about by 5 weeks lithium treatment. The Wnt
signalling dysfunctions, previously reported in these mice [25],
may underlie the unfruitful effects of lithium treatment. As recently
proposed for AD patients [40], it is conceivable that also in mouse
models of AD, characterized by robust amyloid deposition and tau
hyperphosphorylation, an extended period of lithium treatment
might be necessary to counteract the disrupted Wnt/b-catenin
signalling, neurogenesis and cognitive impairments. However,
according to Tariot and Aisen [41] the lithium story in AD could
end here and the discovery of novel agents able to attack and untie
tangles represents a new hope in the therapy of AD.
In conclusion, this is the first comprehensive in vivo study that
provides evidence that lithium, when given on time to Tg mice,
significantly increased cell proliferation, neuronal differentiation,
survival and maturation of newborn cells in the SGZ-GCL and
significantly ameliorated behavioural performances. The lithium-
induced reduction in Ab burden may underlie its effectiveness on
neurogenesis and cognitive functions. Consistent with recent studies,
we demonstrated that lithium by the inhibition of GSK-3b increased
b-catenin expression throughout the neocortex and hippocampus of
TgCRND8 mice and thus the aforementioned results may be an
outcome of activated Wnt/b-catenin signalling. Noteworthy, the
lithium’s ability to stimulate hippocampal neurogenesis and to
recover cognitive functions declined as brain Ab deposits increased
as a function of age. Overall, our findings provide a platform for
further evaluating compounds and strategies targeted at stimulating
neurogenesis for treating or preventing AD in humans. As we were
submitting the manuscript, the P7C3 compound capable of enhanc-
ing survival and integration of new hippocampal neurons, as well as
memory, in mice and rats was discovered [42].
Figure 10. ‘‘Step-down’’ inhibitory avoidance task in saline- and lithium-treated 3- and 7-month-old wild type and TgCRND8 mice.
No statistically significant differences are present in the mean training latencies among groups. In the group of 3 months of age, one-way ANOVA
plus Bonferroni’s post comparison test shows a statistically significant increase in the mean retention latencies in saline- and lithium-treated wt and
lithium-treated Tg mice, as compared to their respective training latencies, *P,0.001. Saline-treated Tg mice do not show significant differences
between training and retention latencies (P.0.05). The retention latencies of saline-treated Tg mice significantly differ from the retention latencies of
all the other groups (1P,0.001). In the group of 7 months of age, one-way ANOVA plus Bonferroni’s post comparison test shows a statistically
significant increase in the mean retention latencies in saline-and lithium-treated wt mice, as compared to their respective training latencies, *P,0.05.
No significant differences are revealed between training and retention latencies in saline-and lithium- treated Tg mice (P.0.05). The retention
latencies of saline-and lithium-treated Tg mice are significantly different from the retention latencies of all other groups (1P,0.05). Data are reported
as mean 6 S.E.M. White bars = training latencies, black bars = retention latencies, S = saline, L = lithium, Tg: TgCRND8, wt: wild type.
doi:10.1371/journal.pone.0014382.g010
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Materials and Methods
Ethics Statement
TgCRND8 and wild type mice were housed in macrolon cages
with ad libitum food and water and maintained on a 12 hr light/
dark cycle at a room temperature of 23uC. All experiments were
carried out according to the ECC guidelines for animal care
(DL 116/92, application of the European Communities
Council Directive 86/609/EEC) and all efforts were made to
minimize animal suffering. The protocols were approved by the
National Committee for animal research, Italy (Permit number:
141/2008-B).
Figure 11. Effects of chronic lithium treatment on Morris water maze performances of wild type and TgCRND8 mice. A,B: training
trials. Latencies to find the platform during the training session are reported as mean 6 S.E.M. Each point represents the mean daily values of four
trials per day. Statistics were performed using one-way ANOVA plus Bonferroni’s post comparison test. In the group of 3 months of age, the saline-
and lithium-treated wt mice show significantly shorter escape latencies with respect to saline-treated Tg mice over sessions (day 1: NP,0.05, days 2–4:
*P,0.001). In lithium-treated Tg mice the recorded latencies are significantly higher than those of saline-treated Tg mice (day 2: uP,0.05; day 3:
NP,0.05 and day 4: *P,0.001) and of saline- and lithium-treated wt mice (day 1: NP,0.05). In the group of 7 months of age, saline-and lithium-treated
wt mice perform at significantly shorter latencies as compared to the Tg groups over sessions (***P,0.001 saline-treated wt vs saline-treated Tg;
**P,0.01 saline- and lithium-treated wt vs lithium-treated Tg mice *P,0.05 lithium-treated wt vs lithium-treated Tg). C, D: bar graphs showing the
percentage of time spent in the target section during the probe trial within 30 s. Data are reported as mean6 S.E.M. Statistics were performed using
one-way ANOVA plus Bonferroni’s post comparison test. In the group of 3 months of age, saline-treated Tg mice spend a significantly shorter
percentage of time in the target section than saline- and lithium-treated wt mice (*P,0.01) and lithium-treated-Tg mice (NP,0.05). In the group of 7
months of age, saline- and lithium-treated Tg mice are significantly impaired as compared to wt groups (*P,0.01). Top left is depicted the target
section of the Morris water maze between red lines.
doi:10.1371/journal.pone.0014382.g011
Lithium on AD-Like Pathology
PLoS ONE | www.plosone.org 15 December 2010 | Volume 5 | Issue 12 | e14382
Animals
Transgenic hemizygous TgCRND8 (Tg) mice and wild type (wt)
control littermate male and female mice, aged 2 and 6 months,
were used. Of note, in this mouse strain amyloid deposition is
already detectable at 3 months of age [21], becoming robust and
widespread at 7 months of age [17]. TgCRND8 mice encode a
double-mutant form of amyloid precursor protein (APP) 695
(KM670/671NL+V717F) under the control of the PrP gene
promoter [21].
Lithium chloride and BrdU treatments
Two groups of TgCRND8 and wt mice, aged 2 months (Tg
n=8, wt n= 8) and 6 months (Tg n=8, wt n= 8), were dosed with
LiCl (Sigma-Aldrich, MI, Italy), or vehicle (0.9% saline). LiCl is
used therapeutically at plasma concentrations between 0.2 and 1.5
milliequivalents (mEq) per liter for the treatment of bipolar
disorders. TgCRND8 and wt mice received intraperitoneal (i.p.)
injections of either 0.6 M LiCl (10 ml/g of body weight) or sterile
saline daily for 5 weeks. This dosing paradigm was previously
described by Noble et al. [43] and in our experimental condition
resulted in plasma concentration of 0.223 mEq/liter 24 h after
injection (n = 6), indicating that plasma lithium was maintained at
physiologically relevant levels.
Cell proliferation and survival. To evaluate proliferation
of neural progenitor cells, lithium- or saline-treated mice
were administered with 5-bromo-29-deoxyuridine (BrdU, Sigma-
Aldrich, MI, Italy) (50 mg/kg of body weight) twice a day for three
days and, 24 h after the last BrdU injection, mice were sacrificed
(n = 5–6/group).
To assess survival of newly generated neurons, an additional
group of 2-month-old wt and Tg mice treated for 5 weeks with
saline or lithium, as described above, was administered with BrdU
(50 mg/kg of body weight) twice a day during the last 3 days of
saline or lithium treatment and sacrificed 5 weeks after the last
BrdU administration (n= 4/group).
Behavioral experiments
Tg- and wt-treated mice were behaviourally tested in the ‘‘Step-
down’’ inhibitory avoidance test at the end of the 4th week of
treatment and in the Morris water maze (MWM) test during the
week 5th of treatment (n = 5–6/group for 3-month-old and n=8/
group for 7-month-old mice).
‘‘Step-Down’’ inhibitory avoidance test. The apparatus
and procedures used were previously described [24]. Briefly, the
inhibitory avoidance apparatus consisted of an open field grey
plexiglas box (40640 cm) with a steel rod floor. The plexiglas
platform (46464 cm) was set in the center of the grid floor.
Intermittent electric shocks (20 mA, 50 Hz) were delivered to the
grid floor by an isolated stimulator. On the first day (training test),
each mouse was gently placed on the platform. When the mouse
stepped down from the platform and placed all its paws on the grid
floor an intermittent electric shock was delivered for 3 seconds (s).
Responsiveness to the punishment in the training test was assessed
by the animal’s vocalization, only those mice that vocalized
touching the grid with the four paws were used for the retention
test in order to exclude the mice with a different pain threshold.
Twenty-four hours (retention test) after training, each mouse was
placed on the platform again. The latencies were measured,
considering 30 s as the upper cut-off, during the training and
retention tests. The tests were carried out between 10:00 A.M. and
1:00 P.M.
Morris Water Maze test (MWM). The water maze
apparatus consisted of a circular pool (1.2 m in diameter and
0.47 m high) made of white plastic. The pool was filled to a depth
of 20 cm with water (24u–25uC) that was made opaque by the
addition of non-toxic white paint. Tg and wt mice, treated with
lithium or saline 0.9% were tested at week 5 of treatment in the
reference memory version of MWM. We applied some
modifications [44] to the method described by Chishti et al. [21]
and Janus et al. [45]. Briefly, all mice underwent a reference
memory training with a hidden platform (10 cm in diameter,
submerged 0.5 cm under the water level), placed in the centre of
one quadrant of the pool (northwest) for 4 days, with 4 trials per
day, with the four starting locations varied between trials. If the
platform was not located within the maximum time of 60 s, the
mouse was guided to the location. The mouse was allowed 20 s on
the platform. Extra-maze visual cues around the room remained in
fixed positions throughout the experiment. For each trial, latency
to find the platform (maximum 60 s) was recorded by a video-
tracking/computer-digitizing system (HVS Image, Hampton,
UK). On day 4, five hours after the last trial, the platform was
removed from the pool and each mouse received one 30 s swim
‘‘probe trial’’. The starting point was set in the south-east
quadrant. Percentage of time spent in the target sector was
recorded.
Processing of animal tissue
At the end of behavioral tests, the mice were sacrificed by cervical
dislocation and brains were rapidly removed and divided sagittally.
Cortical and hippocampal samples from one hemibrain were
immediately sectioned, snap-frozen and stored at280uC in order to
be processed for protein analysis. The other hemibrain was
postfixed in phosphate-buffered 4% paraformaldehyde, pH 7.4, at
4uC for 48 h, then rinsed in PBS and paraffin embedded.
Immunohistochemistry. Immunohistochemical analyses
were performed on 5 mm coronal paraffin-embedded sections
prepared as previously described [24]. Briefly, sections were
incubated overnight at 4uC with the primary antibodies, at the
optimized working dilution, made up in PBS 0.1 M (pH 7.4) with
Triton X-100 (0.3%) and BSA (5 mg/ml). On the second day,
sections were incubated for 1 h with the secondary antibody at
1:1000 dilution made up in PBS 0.1 mM plus BSA (1 mg/ml) and
the immunostaining was visualized using the avidin-biotin system
(Vectastain: Vector Laboratories, Burlingame, CA) and 3,39-
diaminobenzidine plus Nickel (DAB Kit: Vector Laboratories,
Burlingame, CA) as the chromogen and observed by means of a
light microscopy (Olympus BX40, MI, Italy). All primary antibody
concentrations were titrated to provide optimal staining.
Fluorescent staining. Fluorescent labeling followed pre-
viously described protocols [25]. Briefly, coronal brain sections
were rinsed 3 times then placed in blocking solution (PBS,
pH 7.4+0.3% Triton X-100, 2g/l BSA and 5% NGS for
polyclonal antibodies or 5% NHS for monoclonal antibodies), for
30 min at RT. Primary antibodies were diluted in fresh blocking
solution and applied overnight at 4uC. Next, sections were washed
in PBS (3610 min) at room temperature and subsequently
incubated for 2 h in the dark with the appropriate fluorescent
secondary antibody (monoclonal antimouse Alexa Fluor 594 red
conjugated and polyclonal anti-rabbit or anti-goat Alexa Fluor 488
green conjugated, Invitrogen, Eugene, OR) diluted 1:200 in
blocking solution. Following 3 additional rinses, sections were
finally coverslipped using Vectashield water-based mounting
medium with DAPI (Vector Laboratories, Burlingame, CA). The
analysis of negative controls (omission of primary antibody) was
simultaneously performed in order to exclude the presence of
non-specific immunofluorescent staining, cross-immunostaining, or
fluorescence bleed-through. All the primary antibodies used in the
study are listed in Table 1.
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Ab plaque-load determination. To quantify Ab plaque
burden, neocortices and hippocampi of the sections stained with
anti-Ab (1–42) antibody were digitized (Olympus BX40, Olympus,
Hamburg, Germany) under constant light and filter settings. Six to
seven coronal brain sections, each separated by 60 mm interval,
from each mouse (5–6 animals per group) were analyzed.
Morphometry was conducted by using analySIS 5 software (Soft
Imaging System, Mu¨nster, Germany). Colour images were
converted to greyscale by extracting blue to grey values to
obtain best contrast between positive immunoreactivity and
background. A constant threshold was chosen for all images to
detect immunoreactive staining. Plaque number, size (maximum
area, minimum area) and total area were determined
automatically in the parietal neocortices and hippocampus.
Brain regions were based on the Paxinos and Franklin mouse
brain atlas [46]. Data from the six-seven sections were summed to
derive representative values for each animal for the total plaque
area. Data were expressed as mean 6 S.E.M.
Thioflavine S staining. 5-mm-thick, paraffin-embedded
rehydrated sections were incubated with 0.25% KMnO4 for
4 minutes (min), washed with water, incubated with a solution of
0.1% NaBH4 for 5 min and then placed in a high-concentration
PO4 buffer (411 mM NaCl, 8.1 mM KCl, 30 mM Na2HPO4,
5.2 mM KH2PO4) pH 7.2 for 30 min. After washing Thioflavine
S (Sigma-Aldrich, MI, Italy) staining was performed according to
the method described by Yamamoto and Hirano [47] and the
staining was observed using a fluorescence microscope (Olympus
BX40, MI, Italy).
BrdU labeling and counting
For BrdU labeling, sections were treated with 0.6% H2O2 in
Tris-buffered saline (TBS; pH 7.5) to block endogenous peroxi-
dases. DNA was denatured by exposing sections to 2N HCl for
15 min at 37uC followed by 0.1M borate buffer (pH=8.5) for
10 min at room temperature (RT). Sections were then incubated
in TBS with 0.1% Tween-20 (TBS-Tween-20), 1% BSA and 3%
NHS, and then overnight at 4uC with the primary antibody anti-
BrdU in the same buffer. On the second day, sections were washed
(3610 min) in TBS-Tween-20 at RT and subsequently incubated
for 2 h in the dark with the appropriate fluorescent secondary
antibody (polyclonal anti-rat Alexa Fluor 488 green conjugated,
Invitrogen, Eugene, OR) diluted 1:500 in blocking solution. After
washes (3610 min) with TBS–Tween-20 and briefly with water,
sections were finally cover-slipped using Vectashield water-based
mounting medium with DAPI (Vector Laboratories, Burlingame,
CA).
An Olympus BX40 microscope coupled to analySIS‘B Imaging
Software (Olympus, MI, Italy) was used to acquire representative
images from the examined specimens.
Quantification of BrdU positive (BrdU+) cells was performed in
the SGZ and in the GCL (SGZ-GCL) of the hippocampus in 6
coronal sections per mouse spaced at 80 mm. All assessments were
done by experimenters who were blind to the genotype of each
brain section. The counts were conducted at 406magnification
with an Olympus BX40 microscope. The corresponding surface
area of SGZ-GCL sampled was measured using the analySIS‘B
Imaging Software. The density of BrdU+ cells was calculated by
dividing the number of BrdU+ cells by SGZ-GCL sectional area
(mm2).
Determination of phenotype and quantification of
newborn BrdU+ neurons
Proliferation. To establish cell phenotype double-immuno-
fluorescent labeling of BrdU with the marker for immature
neurons doublecortin (DCX) or astrocytes (GFAP) was performed.
Sections (6 per mouse spaced at 80 mm) pretreated for BrdU
staining, were incubated with the second primary antibody in the
dark overnight at 4uC in blocking solution. On the following day,
sections were rinsed (3610 min) with TBS-Tween-20 at RT and
subsequently incubated for 2 h in the dark with the secondary
fluorescent antibody (polyclonal anti-rabbit Alexa Fluor 594 red
conjugated, Invitrogen, Eugene, OR) diluted 1:500 in blocking
solution. After washes (3610 min) with TBS-Tween-20 and briefly
with water, sections were finally cover-slipped using Vectashield
water-based mounting medium with DAPI (Vector Laboratories,
Burlingame, CA).
Table 1. Antibodies employed in the study.
Antibody Specific Dilution Host Source
WB IHC
Ab (1–42) Ab peptide, aa 1–42 Not done 1:200 Rabbit Biosource
PHF-1 phosphorylated tau at S396–S404 1:2000 Not done Mouse P. Davies
p-GSK3a/b phosphorylated GSK-3 a at T279 and b at T216 1:1000 1:100 Rabbit Biosource
p-GSK3b(Ser 9) phosphorylated GSK-3 b at Ser 9 1:1000 1:100 Rabbit Cell Signaling
GSK 3b Total GSK-3 b protein 1:1000 Not done Rabbit Cell Signaling
BrdU Bromodeoxyuridine Not done 1:150 Rat Abcam
DCX Doublecortin Not done 1:500 Rabbit Abcam
NeuN neuronal nuclei Not done 1:100 Mouse Chemicon
b-catenin Total b-catenin (C-terminus) Not done 1:20 Goat Santa Cruz
GFAP Glial fibrillary acidic protein 1:10000 1:500 Rabbit Dako
Iba-1 Ionized calcium binding adaptor molecule 1 Not done 1:250 Rabbit Wako
p-APP(Thr668) Phosphorylated human APP 695 at Thr 668 1:1000 Not done Rabbit Millipore
p-Akt(Ser 473) Phosphorylated Akt at Ser 473 1:1000 Not done Rabbit Cell Signaling
Actin C-terminal actin fragment (C11) 1:5000 Not done Rabbit Sigma-Aldrich
Legend: aa, amino acid; WB, western blot; IHC, immunohistochemistry.
doi:10.1371/journal.pone.0014382.t001
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Quantification of new born immature neurons was calculated as
the percentages of BrdU+ cells expressing DCX in SGZ-GCL. The
GFAP marker was used to exclude a glial phenotype of new born
cells.
Cell Survival. To evaluate the survival of newborn cells
triple-immunofluorescent labeling of BrdU with markers for
mature neurons (NeuN) and for astrocytes (GFAP) was
performed. Sections (6 per mouse spaced at 80 mm) after BrdU
staining were incubated with NeuN in the dark overnight at 4uC in
blocking solution. The next day, sections were rinsed (3610 min)
with TBS-Tween-20 at RT and incubated for 2 h in the dark with
the fluorescent secondary antibody (anti-mouse Alexa Fluor 594
red conjugated, Invitrogen, Eugene, OR) diluted 1:500 in blocking
solution. After washes (3610 min) with TBS-Tween-20, sections
were incubated with GFAP in the dark overnight at 4uC in
blocking solution. The third day, sections were rinsed (3610 min)
with TBS-Tween-20 at RT and incubated for 2 h in the dark with
the fluorescent secondary antibody (anti-rabbit Alexa Fluor 350
blue conjugated, Invitrogen, Eugene, OR) diluted 1:500 in
blocking solution. Subsequently sections were rinsed (3610 min)
with TBS-Tween-20 and briefly with water and finally cover-
slipped using Vectashield water-based mounting medium.
The density of newborn mature neurons was calculated by
dividing the number of BrdU+ cells expressing NeuN by SGZ-
GCL sectional area (mm2).
In every study the analysis of negative controls (omission of
primary antibody) was simultaneously performed in order to
exclude the presence of non-specific immunofluorescent staining,
cross-immunostaining, or fluorescence bleed-through.
Western blotting analysis
Tissue samples were homogenized in ice-cold lysis buffer
containing 2 mM NaPP, 4 mM PNFF, 1 mM Na3VO4, 1mM
PMSF, 20 mg/ml leupeptin, 30 ml/ml aprotinin. Equal amounts of
protein samples (40 mg) were applied to SDS-polyacrylamide gels
and subjected to electrophoresis as previously described [25].
Bands were normalized to b-actin level to provide a control for
equal loading.
Data Analysis
The MWM training data and phospho-GSK-3b(Ser9) and
phospho-Akt levels were analyzed by two-way-ANOVA followed
by Bonferroni’s post comparison test. One-way ANOVA, followed
by Bonferroni’s post-hoc test, was used to analyse the density of
BrdU+ cells. Student’s t-test was used to analyse Ab plaque burden
and PHF-1, phospho-GSK3b(Tyr216), phospho-APP(Thr668)
levels. Statistical analyses were carried out with GraphPad Prism
4 and statistical significance was defined as P,0.05. Data are
reported as mean values 6 standard error of the mean (S.E.M).
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